Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis

Biochemical and Biophysical Research Communications

Volumn 355, Issue 2, 2007, Pages 392-397

  van Lieshout, Antoine W T ^a   Popa, Calin ^a   Meyer Wentrup, Friederike ^a   Lemmers, Heidi L ^a   Stalenhoef, Anton F ^a   Adema, Gosse J ^a   van Riel, Piet L C M ^a   van Tits, Lambertus J ^a   Radstake, Timothy R D J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Chemokine; CXCL16; Oxidized LDL; Rheumatoid arthritis

Indexed keywords

APOLIPOPROTEIN B; CHEMOKINE; CXCL16 CHEMOKINE; IMMUNOGLOBULIN G ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; POLYCLONAL ANTIBODY;

ADULT; ANGINA PECTORIS; ARTHRITIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOPRECIPITATION; INTERNALIZATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CHEMOKINES, CXC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEINS, LDL; MIDDLE AGED; RECEPTORS, SCAVENGER;

EID: 33847125711     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.01.161     Document Type: Article

References (37)

1. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138 (1999) S419-S420
2. Stoll G., and Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 37 (2006) 1923-1932
3. Shashkin P., Dragulev B., and Ley K. Macrophage differentiation to foam cells. Curr. Pharm. Des. 11 (2005) 3061-3072
4. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81 (1984) 3883-3887
5. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol. Pharm. Bull. 26 (2003) 1-9
6. Ehara S., Ueda M., Naruko T., Haze K., Itoh A., Otsuka M., Komatsu R., Matsuo T., Itabe H., Takano T., Tsukamoto Y., Yoshiyama M., Takeuchi K., Yoshikawa J., and Becker A.E. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
7. Holvoet P., Mertens A., Verhamme P., Bogaerts K., Beyens G., Verhaeghe R., Collen D., Muls E., and Van de W.F. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 844-848
8. Holvoet P., Harris T.B., Tracy R.P., Verhamme P., Newman A.B., Rubin S.M., Simonsick E.M., Colbert L.H., and Kritchevsky S.B. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1444-1448
9. Hulthe J., and Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1162-1167
10. Toshima S., Hasegawa A., Kurabayashi M., Itabe H., Takano T., Sugano J., Shimamura K., Kimura J., Michishita I., Suzuki T., and Nagai R. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2243-2247
11. van Tits L.J., van Himbergen T.M., Lemmers H.L., de G.J., and Stalenhoef A.F. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185 (2006) 307-312
12. Rader D.J., Hoeg J.M., and Brewer Jr. H.B. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann. Intern. Med. 120 (1994) 1012-1025
13. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frohlich J., Jungner I., and Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
14. Shimaoka T., Kume N., Minami M., Hayashida K., Kataoka H., Kita T., and Yonehara S. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J. Biol. Chem. 275 (2000) 40663-40666
15. Tabata S., Kadowaki N., Kitawaki T., Shimaoka T., Yonehara S., Yoshie O., and Uchiyama T. Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells. J. Leukoc. Biol. 77 (2005) 777-786
16. Wagsater D., Olofsson P.S., Norgren L., Stenberg B., and Sirsjo A. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem. Biophys. Res. Commun. 325 (2004) 1187-1193
17. Minami M., Kume N., Shimaoka T., Kataoka H., Hayashida K., Akiyama Y., Nagata I., Ando K., Nobuyoshi M., Hanyuu M., Komeda M., Yonehara S., and Kita T. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1796-1800
18. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., Hartmann D., Sedlacek R., Dietrich S., Muetze B., Schuster B., Kallen K.J., Saftig P., Rose-John S., and Ludwig A. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J. Immunol. 172 (2004) 6362-6372
19. Matloubian M., David A., Engel S., Ryan J.E., and Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1 (2000) 298-304
20. Jiang X., Shimaoka T., Kojo S., Harada M., Watarai H., Wakao H., Ohkohchi N., Yonehara S., Taniguchi M., and Seino K. Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J. Immunol. 175 (2005) 2051-2055
21. Nakayama T., Hieshima K., Izawa D., Tatsumi Y., Kanamaru A., and Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol. 170 (2003) 1136-1140
22. Sheikine Y., Bang C.S., Nilsson L., Samnegard A., Hamsten A., Jonasson L., Eriksson P., and Sirsjo A. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis (2005)
23. Boers M., Dijkmans B., Gabriel S., Maradit-Kremers H., O'Dell J., and Pincus T. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum. 50 (2004) 1734-1739
24. Kim S.H., Lee C.K., Lee E.Y., Park S.Y., Cho Y.S., Yoo B., and Moon H.B. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol. Int. 24 (2004) 230-233
25. Svenson K.L., Lundqvist G., Wide L., and Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 36 (1987) 940-943
26. Wallberg-Jonsson S., Cvetkovic J.T., Sundqvist K.G., Lefvert A.K., and Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J. Rheumatol. 29 (2002) 875-882
27. Kim C.H., Kunkel E.J., Boisvert J., Johnston B., Campbell J.J., Genovese M.C., Greenberg H.B., and Butcher E.C. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J. Clin. Invest. 107 (2001) 595-601
28. Ruth J.H., Haas C.S., Park C.C., Amin M.A., Martinez R.J., Haines III G.K., Shahrara S., Campbell P.L., and Koch A.E. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 54 (2006) 765-778
29. van der Voort R., van Lieshout A.W., Toonen L.W., Sloetjes A.W., van Den Berg W.B., Figdor C.G., Radstake T.R., and Adema G.J. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum. 52 (2005) 1381-1391
30. Nanki T., Shimaoka T., Hayashida K., Taniguchi K., Yonehara S., and Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 52 (2005) 3004-3014
31. Prevoo M.L., 't Hof M.A., Kuper H.H., van Leeuwen M.A., van De Putte L.B., and van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38 (1995) 44-48
32. le Blanc L.M., van Lieshout A.W., Adema G.J., van Riel P.L., Verbeek M.M., and Radstake T.R. CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. Neurosci. Lett. 397 (2006) 145-148
33. Sheikine Y., Bang C.S., and Sirsjo A. Can CXCL16 be linked to coronary vascular disease? We still know too little. Atherosclerosis (2006)
34. van Lieshout A.W., Popa C., van Riel P.L., and Radstake T.R. Can CXCL16 be linked to coronary vascular disease? Comment on the article by Sheikine et al. Atherosclerosis (2006)
35. Wuttge D.M., Zhou X., Sheikine Y., Wagsater D., Stemme V., Hedin U., Stemme S., Hansson G.K., and Sirsjo A. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 750-755
36. Shimaoka T., Nakayama T., Hieshima K., Kume N., Fukumoto N., Minami M., Hayashida K., Kita T., Yoshie O., and Yonehara S. Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain. J. Biol. Chem. 279 (2004) 26807-26810
37. Aslanian A.M., and Charo I.F. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 114 (2006) 583-590